ArticleHuman vaccines & immunotherapeutics2025
Next-generation sequencing identifies potential mechanisms of primary resistance to trastuzumab-containing therapies in HER2-positive gastric cancer: Analysis based on real-world data and online databases.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ITHindex: An integrated web-based platform for intratumor heterogeneity evaluation.PLOS digital health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trastuzumab-containing therapy remains a treatment option for patients with HER2-positive gastric cancer (GC). However, primary resistance to trastuzumab is a challenge. Therefore, it is essential to identify biomarkers for predicting the efficacy of trastuzumab-based treatment. First, we retrospectively collected the clinical data of HER2-positive GC patients receiving trastuzumab-containing therapies at the Affiliated Hospital of Qingdao University from October 2019 to August 2024. The patients were divided into long-term and short-term response groups according to progression-free survival (PFS) time, treatment lines and regimens. The next-generation sequencing (NGS) results of these patients were analyzed to identify biomarkers for predicting the efficacy of trastuzumab-containing therapies. Next, the cBioPortal database and LAVA database were screened to explore molecular profiling data. A total of 38 patients were included at our center and were categorized into a responder group (N = 28) and a nonresponder group (N = 10).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.